Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.48 |
| ▸ | PARP1 | P09874 | 3/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.43 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25093449 | 0.85 | PARP1 (0.49) | BACE1PARP1GPR119 | |
| SCHEMBL30212537 | 0.84 | BACE1 (0.52) | BACE1PARP1MAPTMEN1TSHR | |
| SCHEMBL22912731 | 0.84 | BACE1 (0.52) | BACE1PARP1MAPTMEN1TSHR | |
| SCHEMBL30212597 | 0.83 | BACE1 (0.56) | BACE1MAPTMEN1TSHRKMT2A | |
| SCHEMBL29790202 | 0.83 | BACE1 (0.53) | BACE1PARP1MAPTMEN1TSHR | |
| SCHEMBL25543742 | 0.83 | BACE1 (0.53) | BACE1PARP1GPR119MAPTMEN1 | |
| SCHEMBL22912768 | 0.83 | BACE1 (0.53) | BACE1PARP1MAPTMEN1TSHR | |
| SCHEMBL22912729 | 0.83 | BACE1 (0.56) | BACE1MAPTMEN1TSHRKMT2A | |
| SCHEMBL30638885 | 0.83 | BACE1 (0.53) | BACE1PARP1GPR119MAPTMEN1 | |
| SCHEMBL16040669 | 0.83 | GPR119 (0.52) | GPR119MAPTMEN1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343710-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. | 2024-10-17 | — | — | US | disclosed |
| WO-2024178127-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| EP-4326720-A1 | PARP1 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-117177972-A | PARP1 inhibitors and uses thereof | 新特拉有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-04-27 | — | — | US | disclosed |
| US-11591331-B2 | PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11591331-B2 | PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220348574-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2022-11-03 | — | — | US | disclosed |
| WO-2022225934-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | BACE1 1449/4885PARP1 1/4885GPR119 3965/4885 |
| US-20240343710-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PARP1, PARP11, PARP12 | BACE1 1468/4885PARP1 1/4885GPR119 2236/4885 |
| US-20220348574-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | BACE1 1449/4885PARP1 1/4885GPR119 3965/4885 |
| US-11591331-B2 | PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | BACE1 1449/4885PARP1 1/4885GPR119 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.